Navigation Links
Xenon Announces Appointment of EVP, Research & Development
Date:2/13/2013

VANCOUVER, British Columbia, Feb. 13, 2013 /PRNewswire/ -- Xenon Pharmaceuticals Inc. is pleased to announce the appointment of Gary J. Bridger PhD as Executive Vice President, Research and Development.

"We are delighted to welcome Gary to the Xenon team," commented Simon Pimstone , Xenon's President and CEO. "As a co-founder and CSO of AnorMED, he was responsible for the development of MOZOBIL, a hematopoietic stem cell mobilizing agent for non-Hodgkin's lymphoma and multiple myeloma patients, from discovery through completion of phase III trials.  Having also held an executive position at Genzyme, Gary will bring a unique experience to Xenon of small and large public biotech and orphan drug development. I am confident that Gary will make many major contributions to Xenon's future growth."

Dr. Bridger has spent over 20 years in the life sciences industry including positions at Johnson Matthey, AnorMED and Genzyme. Dr. Bridger was a primary member of the team that managed AnorMED's acquisition by Genzyme for US$580 million. Prior to joining Xenon he was a partner with Ventures West Capital Management and he currently serves on the Scientific Advisory Board of Alectos Pharmaceuticals. Dr. Bridger received his PhD in Organic Chemistry from the University of Manchester UK and completed a post-doctoral fellowship at Boston College.  He is the co-author of more than 90 peer-reviewed publications and 40 granted US patents, mainly in the field of chemokine receptor antagonists.

About Xenon Pharmaceuticals Inc. Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing novel therapies for rare diseases. For more information, visit the Company's website at http://www.xenon-pharma.com.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.


'/>"/>
SOURCE Xenon Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BiOptix announces expansion of Innovators Program at Molecular Med TRI-CON 2013
2. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
3. OrbusNeich Announces Favorable Ruling From the European Patent Office
4. Trovagene Announces Commercial Launch Timelines for HPV Carrier and Oncogene Mutation Tests
5. Comprehensive Care Corporation Announces New Medicare Contract with Humana Health Plan of California, Inc.
6. Unilife Corporation Announces Financial Results For Fiscal Year 2013 Second Quarter
7. Regeneron Announces Receipt of Hart-Scott-Rodino Notice
8. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
9. Depomed Announces Appointment of Vicente J. Anido, Jr., Ph.D. to Board of Directors, and Retirement of Directors Julian N. Stern and Craig R. Smith, M.D.
10. CPhI Announces its 2nd Annual Global Pharma Regulatory Summit
11. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)...  Digital Pharmacist Inc. ( ... digital health company, announced today that it has ... to manage their prescriptions. Over three hundred pharmacy ... Pharmacy, USave Pharmacy and Owen,s Healthcare use the ... its product development schedule, the company now powers ...
(Date:3/23/2017)... Research and Markets has announced the addition ... their offering. ... The global capillary electrophoresis market to grow at a CAGR of ... Capillary Electrophoresis Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:3/23/2017)... Newborns are highly vulnerable to infections ... their young immune systems typically mount weak antibody ... achieving strong vaccine responses in newborn animals, including ... trials — by adding compounds known as adjuvants ... papers, they also describe improved adjuvant formulations that ...
Breaking Medicine Technology:
(Date:3/23/2017)... Texas (PRWEB) , ... March 23, 2017 , ... The ... 3rd location in the greater Houston Area. The new location is located at 2255 ... Luke’s Hospital in Springwoods Village. This newest location will provide patients living in the ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy ... 960 Gruene Road in Building 2. The clinic is the group’s second in New ... says opening the company’s second New Braunfels location brings things full circle for the ...
(Date:3/23/2017)... ... ... The IoT (Internet of Things) is revolutionizing the way the world operates. ... individual consumers alike. Laboratories can maximize their profit margin by increasing throughput. ... to $11 trillion dollars by the year 2025. McKinsey expects the IoT to have ...
(Date:3/23/2017)... ... , ... 82% of adults are unaware of the dangers that infectious bacteria play in mouth ... two times a day that dentists recommend. The ramifications of improper oral upkeep go far ... adults missing 164 million hours of work each year due to dental issues. That is ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... March is ... that pack a punch when it comes to maintaining good health. Every day, two ... minutes, your kidneys filter every drop of your blood, eliminating waste, regulating fluid levels ...
Breaking Medicine News(10 mins):